FDA Approved: RISPERDAL M-TAB — Supplemental Application (Janssen Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Risperdal M-TAB (risperidone) from Janssen Pharmaceuticals. The notice lists the submission status as AP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder
• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• RISPERDAL M-TAB (Risperidone)

Snippet

SUPPL AP for RISPERDAL M-TAB (RISPERIDONE)